David  Schaffer net worth and biography

David Schaffer Biography and Net Worth

David Schaffer is a Professor of Chemical and Biomolecular Engineering, Bioengineering, and Neuroscience at UC Berkeley, where he also serves as the Director of the Berkeley Stem Cell Center. In addition, he is Co-Founder, Acting CSO, and Co-Chairman of 4D Molecular Therapeutics.

At UC Berkeley, Dr. Schaffer applies engineering principles to enhance stem cell and gene therapy approaches for neuroregeneration, work that includes novel approaches for molecular engineering and evolution of new viral vectors as well as new technologies to investigate and control stem cell fate decisions.

Professor Schaffer served as Dr. Yousef’s co-thesis advisor (2008-2013).

What is David Schaffer's net worth?

The estimated net worth of David Schaffer is at least $1.38 million as of January 17th, 2019. Dr. Schaffer owns 43,701 shares of 4D Molecular Therapeutics stock worth more than $1,378,330 as of March 28th. This net worth estimate does not reflect any other investments that Dr. Schaffer may own. Learn More about David Schaffer's net worth.

How do I contact David Schaffer?

The corporate mailing address for Dr. Schaffer and other 4D Molecular Therapeutics executives is , , . 4D Molecular Therapeutics can also be reached via phone at 510-505-2680 and via email at [email protected]. Learn More on David Schaffer's contact information.

Has David Schaffer been buying or selling shares of 4D Molecular Therapeutics?

David Schaffer has not been actively trading shares of 4D Molecular Therapeutics in the last ninety days. Most recently, David Schaffer sold 1,900 shares of the business's stock in a transaction on Friday, October 22nd. The shares were sold at an average price of $31.00, for a transaction totalling $58,900.00. Learn More on David Schaffer's trading history.

Are insiders buying or selling shares of 4D Molecular Therapeutics?

During the last twelve months, 4D Molecular Therapeutics insiders bought shares 1 times. They purchased a total of 850,000 shares worth more than $13,600,000.00. During the last twelve months, insiders at the sold shares 13 times. They sold a total of 729,381 shares worth more than $15,338,810.08. The most recent insider tranaction occured on March, 18th when insider Scott Bizily sold 1,750 shares worth more than $54,722.50. Insiders at 4D Molecular Therapeutics own 10.7% of the company. Learn More about insider trades at 4D Molecular Therapeutics.

Information on this page was last updated on 3/18/2024.

David Schaffer Insider Trading History at 4D Molecular Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/22/2021Sell1,900$31.00$58,900.00View SEC Filing Icon  
10/20/2021Sell11,565$31.02$358,746.30View SEC Filing Icon  
9/29/2021Sell16,871$28.61$482,679.31View SEC Filing Icon  
9/27/2021Sell19,332$32.89$635,829.48View SEC Filing Icon  
See Full Table

David Schaffer Buying and Selling Activity at 4D Molecular Therapeutics

This chart shows David Schaffer's buying and selling at 4D Molecular Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

4D Molecular Therapeutics Company Overview

4D Molecular Therapeutics logo
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
Read More

Today's Range

Now: $31.54
Low: $30.25
High: $34.20

50 Day Range

MA: $26.76
Low: $17.03
High: $35.87

2 Week Range

Now: $31.54
Low: $9.44
High: $36.25

Volume

1,039,056 shs

Average Volume

1,160,197 shs

Market Capitalization

$1.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.86